Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2026 06:00 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces 1-for-10 Reverse Share Split

Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development...
May 18, 2026 08:42 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development...
May 15, 2026 08:35 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

Federal Officials, Researchers, Clinicians and Biopharma Leadership Convened by Psychedelic Medicine Coalition at the National Press Club Vancouver, Canada, May 15, 2026 (GLOBE NEWSWIRE) -- ...
May 12, 2026 08:41 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

Vancouver, Canada, May 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development...
May 11, 2026 07:55 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a...
May 05, 2026 08:50 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

Vancouver, Canada, May 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development...
April 27, 2026 07:41 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE)...
April 20, 2026 16:03 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and...
April 20, 2026 07:15 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development...
April 15, 2026 07:30 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Vancouver, Canada, April 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and...